Ipragliflozin (INN,[2]: 69  trade names Suglat) is a pharmaceutical drug for treatment of type 2 diabetes.

Ipragliflozin, jointly developed by Astellas Pharma and Kotobuki Pharmaceutical, was approved in Japan on January 17, 2014,[3] and in Russia on May 22, 2019.

SGLT2 is one subtype of SGLTs and plays a key role in the reuptake of glucose in the proximal tubule of the kidneys.

The changes in fasting plasma glucose and bodyweight were also significantly greater in the ipragliflozin group, with between-group differences of −14.1 mg/dL and −1.24 kg, respectively (both p <0.001).

[9] Ipragliflozin was also in development for type 2 diabetes mellitus in the U.S., Europe and other countries, and three phase II trials were completed in combination with metformin.

[13]: 50 In May 2013, Boehringer Ingelheim of Germany applied for a Methods of Treatment, Pharmaceutical Compositions and uses thereof patent.

[16] The National Institute of Biological Science out of Beijing filed a similar patent in September 2015.

In January 2016, the Dalian University of Technology filed a patent on the synthetic method of ipragliflozin.